Abstract Major depressive disorder (MDD) remains a critical global health burden, and a substantial proportion of patients exhibit insufficient responses to conventional monoaminergic antidepressants. Selective inhibition of the two-pore domain potassium channel TREK1 has emerged as a promising antidepressant strategy; however, the regulatory mechanisms controlling TREK1 trafficking—particularly its functional coupling with G protein–coupled receptors (GPCRs)—remain poorly understood.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Hoon
Contact Hoon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack